Low salt forms of polyallylamine
View Patent ↗Disclosed is a pharmaceutical composition comprising a stable polyallylamine hydrochloride polymer in which between about 4% to about 12% by weight of the polymer is a chloride anion and a pharmaceutically acceptable carrier or diluent.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a stable polyallylamine hydrochloride polymer wherein between about 4% to about 12% by weight of the polymer is chloride anion and between about 9.0% to about 27.0% of the amine groups in the polyallylamine polymer are protonated.
2. The pharmaceutical composition of claim 1 wherein between about 5% to about 9% by weight of the polymer is chloride anion.
3. The pharmaceutical composition of claim 2 wherein the polymer is a homopolymer.
4. The pharmaceutical composition of claim 3 wherein the polyallylamine hydrochloride polymer comprises a repeat unit represented by Structural Formula (I):
5. The pharmaceutical composition of claim 4 wherein the polymer is crosslinked.
6. The pharmaceutical composition of claim 5 wherein the polymer is crosslinked with 2-hydroxypropyl crosslinking groups.
7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a stable polyallylamine homopolymer comprising repeat units represented by Structural Formula (I):
wherein the homopolymer is crosslinked with 2-hydroxypropyl groups, between about 9% and about 30% of the amine groups in the homopolymer are bonded to one of the 2-hydroxypropyl crosslinking groups, and between about 5% and about 9% by weight of the homopolymer is chloride anion and between about 9.0% to about 27.0% of the amine groups in the polyallylamine polymer are protonated.